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High Peritoneal Transport Status is Not an Independent  
Risk Factor for High Mortality in Patients Treated with Automated 
Peritoneal Dialysis
We undertook this study to elucidate whether baseline peritoneal membrane transport 
characteristics are associated with high mortality in incident automated peritoneal dialysis 
(APD) patients. This retrospective study includes 117 patients who started APD at Yonsei 
University Health System from 1996 to 2008 and had a PET within 3 months of APD 
initiation. High transporters were significantly older and had a higher incidence of 
cardiovascular disease. Patient survival for years 1, 3, and 5 were 85%, 64%, and 35% for 
high transporter and 94%, 81%, and 68% for non-high transporter group (P<0.01). 
Multivariate analysis revealed that age, diabetes, cardiovascular disease, serum albumin 
level, and residual renal function were independently associated with high mortality in APD 
patients. In contrast, high transport status was not a significant predictor for mortality in 
this population when the other covariates were included. Even though high transport was 
significantly associated with mortality in the univariate analysis, its role seemed to be 
influenced by other comorbid conditions. These findings suggest that the proper 
management of these comorbid conditions, as well as appropriate ultrafiltration by use of 
APD and/or icodextrin, must be considered as protective strategies to improve survival in 
peritoneal dialysis patients with high transport.
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INTRODUCTION
Patients with end-stage renal disease (ESRD), including those 
who are on peritoneal dialysis (PD), are at much higher risk for 
mortality than the general population. Several factors such as 
age, comorbidities including diabetes and cardiovascular dis-
ease (CVD), malnutrition/hypoalbuminemia, reduced residual 
renal function, and inflammation have been associated with 
high mortality in PD patients (1-7). Recently, peritoneal mem-
brane transport status has attracted considerable attention as 
another contributor to decreased survival in these patients.
 High transport status, as defined by the increased ratio of cre-
atinine in the dialysate to plasma after a 4-hr dwell (D/P cr4) from 
a peritoneal equilibration test (PET) (8), has been associated with 
several parameters that in themselves are well-known risk fac-
tors for mortality in PD patients. Diabetes, CVD, hypoalbumin-
emia, poor nutritional status, and inflammation, as well as in-
appropriate ultrafiltration and large peritoneal protein loss have 
been shown to be more prevalent in high transporters compared 
to other peritoneal transporters. These comorbidities may also 
play a role in the higher rate of adverse outcomes observed in 
high transporters (3, 9-13). However, most studies, investigatng 
the adverse effect of high transport status on outcomes in PD 
patients, have been performed in the patients who were mainly 
on continuous ambulatory PD (CAPD), or in largely prevalent 
patient population. The association between high peritoneal 
transport and the long-term survival among the incident patients 
treated with automated PD (APD) has not been fully explored. 
We, therefore, undertook this study to evaluate the impact of 
peritoneal membrane transport characteristics, as measured by 
a PET, on mortality in incident patients who were on APD.
MATERIALS AND METHODS
We retrospectively analyzed a total of 117 patients who started 
APD at Yonsei University Health System from January 1996 to 
December 2008 and had a PET within 3 months of APD initia-
tion. This study was approved by the institutional review board 
(IRB number 4-2009-0680). All subjects were given a standard 
PET using 2.27% glucose PD fluid and were classified into one 
of the four peritoneal transport types according to the value for 
D/P cr4 defined by Twardowski et al. (8): high ≥0.81, high aver-
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age 0.65 to 0.80, low average 0.50 to 0.64, and low <0.50.
 Demographic and clinical data were collected based on ret-
rospective review of patient records. The data included age, gen-
der, body mass index (BMI, weight [kg]/height [m2]), duration 
of PD, cause of ESRD, comorbidities, use of icodextrin, and the 
patient outcome. The following laboratory data obtained at the 
time of PD catheter insertion (within first week after starting PD) 
were considered as baseline: hemoglobin, blood urea nitrogen 
(BUN), serum creatinine, calcium, phosphorus, total cholesterol, 
uric acid, and albumin concentrations, Kt/V urea, percentage 
of lean body mass (%LBM), normalized protein catabolic rate 
(nPCR), and residual glomerular filtration rate (GFR). Cardio-
vascular disease was defined as a history of coronary, cerebro-
vascular, or peripheral artery disease. Coronary disease was de-
fined as a previous history of angioplasty, coronary artery bypass 
graft, myocardial infarction, or angina. Cerebrovascular disease 
was defined as a previous transient ischemic attack, stroke, or 
carotid endarterectomy, and peripheral vascular disease as a his-
tory of claudication, ischemic limb loss, and/or ulceration or a 
peripheral revascularization procedure. Technique failure was 
defined as transfer to hemodialysis due to peritonitis, ultrafiltra-
tion failure, inadequate dialysis, exit and tunnel infection, and 
mechanical problems.
 All values are expressed as mean±standard deviation (SD) or 
percentages. Statistical analyses were performed using SPSS for 
Windows ver 13.0 (SPSS, Inc., Chicago, IL, USA). Data were an-
alyzed using Student’s t-test, chi-square test, or Fisher exact test 
for comparisons. Patient and technique survival was assessed 
using life table methods and comparisons were made with Ka-
plan-Meier analysis and log-rank tests. Patients were censored 
at the point of transplantation or if lost to follow-up. To determine 
risk factors for mortality in APD patients, multivariate Cox regres-
sion was performed, in which we included all of the significant 
covariates from the univariate analysis. A P value less than 0.05 
was considered statistically significant.
RESULTS
Demographic characteristics and clinical data
Table 1 details baseline characteristics of 117 incident APD pa-
tients. The mean age of patients was 49.0 yr (range 20 to 86 yr), 
70.1% were males, and patients were on PD for a mean period 
of 27.8 months (range 3.5 to 155.2 months). Chronic glomeru-
lonephritis was the most common cause of ESRD (34.2%), fol-
lowed by diabetes (29.9%) and hypertension (19.7%). Among 
the 117 patients, 24 patients (20.5%) were high transporters, and 
91 patients (77.8%) used icodextrin. The baseline mean hemo-
globin was 9.6±1.9 g/dL, and serum albumin was 3.5±0.6 g/dL. 
The baseline Kt/V urea and residual GFR were 2.2±0.6 and 2.9 
±3.7 mL/min/1.73 m2, respectively. When the patients were di-
vided into two groups based on a PET, high transporters (High 
group) were significantly older (P<0.05) and had a higher inci-
dence of CVD (P<0.05) compared to non-high transporters (Non-
high group) (Table 2).
Patient outcomes
During the period of study, 66 patients (56.4%) were living on 
APD, and 20 patients (17.1%) died. Infection (50.0%) was the 
Table 1. Demographic and clinical characteristics of the study subjects (n=117)
Characteristics Findings
Age (yr)   49.0±13.2
Gender (male:female) 82:35
BMI (kg/m2) 23.5±3.6
Follow-up duration (months)   27.8±27.7
Underlying renal disease
   Diabetes mellitus (No.)
   Hypertension (No.)
   Chronic glomerulonephritis (No.)
   Polycystic kidney disease (No.)
   Others (No.)
   Unknown (No.)
  35 (29.9%)
  23 (19.7%)
  40 (34.2%)
  2 (1.7%)
  7 (6.0%)
10 (8.5%)
Comorbid conditions
   Diabetes mellitus (No.)
   Cardiovascular disease (No.)
  35 (29.9%)
  40 (34.2%)
Peritoneal equilibration test
   High (No.)
   High-average (No.)
   Low-average (No.)
   Low (v)
  24 (20.5%)
  53 (45.3%)
  37 (31.6%)
  3 (2.6%)
Mean D/P creatinine at 4 hr   0.71±0.12
Use of icodextrin (No.)   91 (77.8%)
Data are expressed as mean±standard deviation.
BMI, body mass index; D/P, ratio of dialysate to plasma.
Table 2. Baseline characteristics in high and non-high transport groups
Variables
High  
(n=24)
Non-high 
(n=93)
P
Age (yr) 54.5±14.2   47.6±12.6
Gender (male:female) 13:11 69:24 NS
BMI (kg/m2) 23.5±2.6 23.5±3.9 NS
Comorbid conditions
   Diabetes mellitus
   Cardiovascular disease
  8 (33.3%)
13 (54.2%)
27 (29.0%)
27 (29.0%)
NS
<0.05
Use of icodextrin 21 (87.5%) 70 (75.3%) NS
Laboratory findings
   Hemoglobin (g/dL)
   BUN (mg/dL)
   Creatinine (mg/dL)
   Calcium-phosphorus product (mg2/dL2)
   Total cholesterol (mg/dL)
   Uric acid (mg/dL)
   Serum albumin (g/dL)
  9.9±1.9
  55.7±30.6
  9.3±3.1
  41.7±12.9
162.0±43.9
  6.5±2.0
  3.3±0.5
  9.6±1.9
  60.5±26.6
  9.7±3.9
  46.2±10.7
171.9±44.0
  7.0±1.7
  3.6±0.6
NS
NS
NS
NS
NS
NS
NS
Urea kinetics
   Kt/V urea
   Lean body mass (% body weight)
   nPCR (g/kg/day)
   Residual GFR (mL/min/1.73 m2)
  2.1±0.7
  68.7±11.0
  0.9±0.2
  4.9±2.9
  2.2±0.6
  73.1±12.0
  1.0±0.3
  5.9±3.8
NS
NS
NS
NS
Data are expressed as mean±standard deviation or number of patients (percent).
BMI, body mass index; BUN, blood urea nitrogen; Kt/V, fractional urea clearance; nPCR, 
normalized protein catabolic rate; GFR, glomerular filfration rate, NS, not significant. 
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most common cause of death, with four patients dying of peri-
tonitis, followed by CVD (40.0%), upper gastrointestinal bleed-
ing (8.3%), and unknown (8.3%). There was a tendency for higher 
incidence of infection in High group (75% vs. 33.3%) and CVD in 
Non-high group (50% vs. 25%), but this difference was not statis-
tically significant. Transfer to hemodialysis occurred in 21 pa-
tients (17.9%), mainly due to peritonitis (57.1%). Other reasons 
of technique failure were ultrafiltration failure (23.8%), inade-
quate dialysis (14.3%), and noncompliance (4.8%). There was no 
difference between either transport groups for the causes of tech-
nique failure. Another 9 patient (7.7%) underwent kidney trans-
plantation, and only 1 patient (0.9%) moved to another center.
Patient survival
Table 3 presents the differences between survivors (n=97) and 
non-survivors (n=20). In non-survival group, diabetes (P<0.001), 
CVD (P<0.001), and high peritoneal membrane transport (P< 
0.05) were more prevalent, and serum albumin level (P<0.001) 
and residual GFR (P<0.001) at baseline were significantly lower 
than those observed in the survivor group. Besides, non-survi-
vors were significantly older than survivors (P<0.001). Fig. 1 shows 
patient survival for both peritoneal membrane transport groups. 
Patient survival for years 1, 3, and 5 were 85%, 64%, and 35% for 
High group and 94%, 81%, and 68% for Non-high group (P<0.01). 
As shown in Table 4, multivariate Cox regression revealed that 
age (P<0.01), diabetes (P<0.05), CVD (P<0.05), serum albumin 
level (P<0.05), and residual GFR (P<0.05) were independently 
associated with high mortality in patients treated with APD. How-
ever, high transport status was not a significant predictor for mor-
tality in this population when the other covariates were included.
Technique survival
Estimated mean pure (death-censored) and combined (patient 
and death-censored) technique survival were 90.5±23.1 and 
49.8±13.1 months in High group, and 100.5±11.9 and 79.1±10.4 
months in Non-high group, respectively. Cumulative combined 
technique survival at the end of 1, 3, and 5 yr were 76%, 57%, 
and 16% for High group, and 83%, 66%, and 30% for Non-high 
group. There were no significant differences in the risk of either 
technique failure between patients in two transport groups.
DISCUSSION
It is well established that PD patients have different peritoneal 
membrane transport properties. These differences can best be 
classified and determined by the use of a PET, which helps to 
characterize the relationships among dwell time, solute trans-
port, glucose absorption, drain volume, and net solute clearance 
(14). Patients who have a greater rate of membrane solute trans-
port are classified as high (or fast) transporters, and will tend to 
have enhanced clearance of small solutes, such as urea and cre-
Table 3. Comparisons between survivors and non-survivors
Variables Survivors (n=97)
Non-Survivors 
(n=20)
P
Age (yr)   46.2±11.6   62.7±12.2
Gender (male:female) 68:29 14:6 NS
BMI (kg/m2) 23.7±3.8 22.3±2.4 NS
Comorbid conditions
   Diabetes mellitus
   Cardiovascular disease
22 (22.7%)
26 (26.8%)
13 (65.0%)
14 (70.0%) 
  <0.001
  <0.001
PET (high:non-high)
   Initial
   Last follow up
16:81
12:53
8:12
5:9
<0.05
NS
Use of icodextrin 77 (79.4%) 14 (70.0%) NS
Laboratory findings
   Hemoglobin (g/dL)
   BUN (mg/dL)
   Creatinine (mg/dL)
   Calcium-phosphorus product 
       (mg2/dL2)
   Total cholesterol (mg/dL)
   Uric acid (mg/dL)
   Serum albumin (g/dL)
  9.5±2.0
  60.8±26.7
  9.9±3.8
  45.6±10.5
170.5±43.5
  7.0±1.7
  3.6±0.6
10.0±1.7
  53.6±30.1
  8.6±3.6
  43.6±14.7
166.8±47.2
  6.5±2.3
  3.1±0.6
NS
NS
NS
NS
NS
NS
<0.001
Urea kinetics
   Kt/V urea
   Lean body mass (% body weight)
   nPCR (g/kg/day)
   Residual GFR (mL/min/1.73 m2)
  2.2±0.7
  72.4±12.1
  1.0±0.2
  6.5±3.6
  1.9±0.4
  71.5±11.3
  0.9±0.2
  2.1±1.6
NS
NS
NS
<0.001
Data are expressed as mean±standard deviation or number of patients (percent).
BMI, body mass index; PET, peritoneal equilibration test; nPCR, normalized protein 
catabolic rate; NS, not significant. 
Fig. 1. Kaplan-Meier survival plots for patient survival according to peritoneal transport 
type. The survival rate was significantly higher for the patients who were in the non-
high transport group (P<0.01).
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Table 4. Multivariate Cox proportional hazard model for patient mortality
Variables HR (95% CI) P
Age (per 1 yr increase) 1.07 (1.03-1.13) <0.01
Diabetes mellitus (yes vs. no)   3.73 (1.33-10.50) <0.05
Cardiovascular disease (yes vs. no)   3.27 (1.02-10.49) <0.05
High peritoneal transport (vs. non-high) 1.24 (0.44-3.53) NS
Serum albumin (per 1 g/dL increase) 0.28 (0.09-0.84) <0.05
Residual GFR (per 1 mL/min/1.73m2 increase) 0.60 (0.36-0.99) <0.05
HR, hazard ratio; CI, confidence interval; NS, not significant.
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atinine, early in short dwells. However, these patients will have 
larger peritoneal loss of protein, will be more likely to fluid over-
load as a result of rapid reabsorption of glucose from the dialy-
sate and subsequent ultrafiltration dysfunction, and will have 
greater systemic exposure to glucose (15-19). In addition, high 
transporters have been associated with poor nutritional status, 
more prevalent comorbid diseases, and chronic inflammation 
(3, 9-13).
 Many conflicting results have been reported on the relation-
ship between high peritoneal transport and mortality in PD pa-
tients. The single-center Stroke PD study (18, 19) and the multi-
center CANUSA study (2) found that high transport was associ-
ated with worse patient and technique survival independent of 
other important risk factors, such as age, comorbidities, and re-
sidual renal function. A recent meta-analysis of 20 observational 
studies (20) also demonstrated that a higher peritoneal mem-
brane solute transport rate was associated with a higher mor-
tality risk and a trend to higher technique failure. However, these 
findings were not confirmed by several other studies including 
ADEMEX trial which showed that high transport does not have 
any influence on patient survival in PD patients (21-23). Further-
more, some investigations have found an association on univar-
iate analysis only, or with morbidity but not mortality (24-26). 
The reasons for these conflicting observations are not clear, but 
most studies investigating outcomes in PD patients have been 
performed in patients who were mainly on CAPD, or included 
a greater portion of prevalent patients. Even though there has 
been a study, with small number of patients, reporting that APD 
patients with high peritoneal transport had a lower probability 
of patient survival, there is some evidence that APD mitigates 
the adverse effects of high transport (27). Most recently, analy-
sis from the ANZDATA registry, by far the largest study publish-
ed to date, has confirmed that peritoneal transport type was only 
a significant predictor of mortality in patients on CAPD, not in 
those on APD (28). In another recent single-center observation 
cohort study (29), high transport status predicted a higher risk 
of death in patients who started PD between 1990 and 1997, but 
not in patients who started PD between 1998 and 2005. During 
the latter vintage, patients were more likely to be treated with 
APD or icodextrin. Similarly, in the EAPOS study (30) of patients 
receiving APD, transport status had no bearing on increased risk 
of death at one year. Taken together, it is likely that an increased 
peritoneal transport rate appears to be less important as a predic-
tor of mortality in APD patients when compared to CAPD patients.
 In the present study, we found that there was a significant dif-
ference, as determined by univariate analysis, in mortality be-
tween high and non-high transporters. However, high transport 
status was confirmed not to be a significant risk factor associat-
ed with mortality of the incident APD patients. This situation was 
particularly evident when adjusted for age and other comorbid-
ities such as diabetes, CVD, serum albumin level, and residual 
GFR. As these are well known risk factors for mortality on PD, it 
is probable that the association seen in this study between high 
transporter and mortality is related to the presence of these co-
morbid conditions. Furthermore, it might be said that the strat-
egies including optimization of the short dwell lengths using 
APD combined with icodextrin which will result in sustained 
ultrafiltration and thus prevention of reabsorption in the long 
dwell have been attributed to minimize the adverse effects of 
high transport on patient survival in these patients.
 There are several limitations in the present study. It was an 
observational study based on retrospective data collected from 
a relatively small sample size. Therefore, the causality of our find-
ings needs further confirmation. Also we did not include other 
relevant data representing overall nutritional status and systemic 
inflammation such as subjective global assessment (SGA) and 
other inflammatory markers to fully assess the impact of nutri-
tional and inflammatory status. Finally, the impact of icodextrin-
based products on mortality could not be evaluated in this study 
because most of our patients were using icodextrin.
 In conclusion, the present study showed that age, diabetes, 
CVD, serum albumin level, and residual GFR were independent 
predictors for mortality in incident PD patients who were on APD. 
Even though high transport was significantly associated with 
mortality in the univariate analysis, this association was not an 
independent risk factor for mortality. Its role seemed to be influ-
enced by other comorbid conditions. These findings suggest that 
the proper management of these comorbid conditions, as well 
as appropriate ultrafiltration by use of APD and/or icodextrin, 
must be considered as a protective strategy to improve survival 
in PD patients with high transport.
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